Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 142.77M | 142.81M | 137.52M | 174.90M | 178.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 142.77M | 142.81M | 137.52M | 174.90M | 178.70M |
| Cost of Revenue | 60.65M | 59.06M | 57.85M | 108.56M | 120.52M |
| Gross Profit | 82.12M | 83.75M | 79.68M | 66.35M | 58.18M |
| SG&A Expenses | 121.41M | 122.88M | 126.49M | 139.49M | 150.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.63M | 269.81M | 276.27M | 341.51M | 368.32M |
| Operating Income | -132.85M | -126.99M | -138.75M | -166.61M | -189.62M |
| Income Before Tax | -153.71M | -163.70M | -184.33M | -213.29M | -242.56M |
| Income Tax Expenses | -- | -- | -- | 0.00 | -380.00K |
| Earnings from Continuing Operations | -153.71 | -163.70 | -184.33 | -213.29 | -242.18 |
| Earnings from Discontinued Operations | 333.46M | 32.76M | 212.84M | 212.84M | 212.84M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 179.75M | -130.94M | 28.51M | -450.00K | -29.34M |
| EBIT | -132.85M | -126.99M | -138.75M | -166.61M | -189.62M |
| EBITDA | -128.21M | -122.18M | -133.47M | -161.30M | -184.97M |
| EPS Basic | 1.54 | -1.13 | 0.27 | -0.01 | -0.32 |
| Normalized Basic EPS | -1.75 | -1.74 | -1.80 | -1.02 | -1.20 |
| EPS Diluted | 1.52 | -1.16 | 0.24 | -0.01 | -0.33 |
| Normalized Diluted EPS | -1.75 | -1.74 | -1.80 | -1.02 | -1.20 |
| Average Basic Shares Outstanding | 462.56M | 461.31M | 458.20M | 454.27M | 436.80M |
| Average Diluted Shares Outstanding | 462.56M | 461.31M | 458.20M | 454.27M | 436.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |